Table 1
Enrolment of minority groups in Phase III trials of SLE
2 3 9 10 14
Trial
n
Location of trial sites
% African
% AI/AN
% Hispanic
BLyS 72
819
North America, Europe
14
13
21
BLyS 56
865
Asia, South America
4
32
49
Tabalumab
2288
Worldwide
11
13
29
Embody
1584
Worldwide
12
Unknown
20
AI, American Indian; AN, Asian.